MIM
RARX

Monashee Investment Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Monashee Investment Management’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-92,043
Closed -$1.68M – 159
2018
Q4 		$1.68M Buy
+92,043
New +$1.45M 1.13% 28
2017
Q1 		– Sell
-15,147
Closed -$290K – 76
2016
Q4 		$230K Buy
+15,147
New +$206K 0.11% 77

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MMPI
Morgenthaler Management Partners IX Portola Valley, California $22.6M AUM
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Monashee Investment Management's RARX Position: Q1 2019 in Review

Monashee Investment Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q1 2019, closing a stake of 92,043 shares — an estimated $1.68M sold.

Monashee Investment Management first reported a position in RARX in Q4 2016 and held it in 2 quarters. The position peaked at $1.68M in Q4 2018. 124 funds tracked by Wall St. Rank hold RARX as of Q1 2019.

  • Monashee Investment Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Monashee Investment Management sold 92,043 Ra Pharmaceuticals, Inc. Common Stock shares in Q1 2019, an estimated $1.68M.
  • Monashee Investment Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 2 quarters.
  • Monashee Investment Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $1.68M in Q4 2018.
  • 124 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q1 2019.

Based on Monashee Investment Management's 13F filing for Q1 2019, filed 13 May 2019.